Isomorphic adds Merck to AI drug discovery roster days after $5B raise

Merck
Merck will work with Isomorphic to discover therapeutic small-molecule candidates against an oncology target. (Angus Liu/Fierce Pharma)

Isomorphic Labs’ big week just got bigger. Days after raising $5 billion, the AI-powered biotech has added Merck & Co. to a list of partners that now includes three of the top four drugmakers by revenue.

Merck will work with Isomorphic to discover therapeutic small-molecule candidates against an oncology target. The partners have yet to disclose the exact target, saying only that it is of “strategic importance.” The deal features an upfront payment, plus research, development, regulatory and commercial milestones and tiered royalties. Isomorphic has an option to co-fund development in return for elevated royalties.

The collaboration pairs the AI approach to drug discovery established by Isomorphic with the data and drug discovery experience of Merck, which does business as MSD outside the U.S.

“The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,” George Addona, head of discovery, preclinical development and translational medicine at MSD Research Laboratories, said in a statement.

“By combining MSD’s substantial internal data capabilities and discovery expertise with Isomorphic Labs’ powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster,” Addona added.

Merck joins the growing list of companies betting that Isomorphic’s modeling and compute capabilities can advance drug discovery. Investors put Isomorphic in the spotlight early this week, pumping $5 billion into the company six months after committing $2.1 billion. But the biotech has also built up a starry list of strategic collaborators. 

London, U.K.-based Isomorphic disclosed a deal with Eli Lilly in 2024 and partnered (PDF) with Johnson & Johnson. In 2025, J&J and Lilly were the first and third largest drugmakers by revenue, respectively. Merck was the fourth-largest drugmaker. Isomorphic is also partnered with Novartis, meaning its publicly disclosed list of collaborators includes four of the top eight drugmakers. 

During a panel on Big Pharma deal-making at Fierce's London Life Sciences Week event on Tuesday, Grace Han McMahon, who leads Pacific business development and licensing for Merck, name-checked the U.K. alongside Boston, San Francisco and Asia as among the “key life sciences ecosystems” where the company has based its discovery scientists.